Abstract
In the tumor environment, interstitial pressure drives interstitial flow drainage from the tumor core to the lymphatic vessels. Recent studies have highlighted the key role of interstitial pressure in tumor development and cell migration. High intratumoral pressures, up to , have been reported in cancer patients. In a previous study, we showed that such pressure levels induce fracture in an experimental tumor model consisting of a microfluidic system holding a cellular aggregate. Here, we investigate and quantify the characteristics of tumor model fracture under a range of flow conditions. Our findings suggest a strong dependence of viscoelastic fracture behavior on the loading rate exerted by flow. The aggregate exhibits fragile fracture at high loading rates and ductile fracture at lower rates. The loading rate also modifies the permeability of the cellular aggregate, as well as the persistence time of the load required to induce fracture. The quantification parameters we propose here, evaluated for an in vitro model tumor without the extracellular matrix, could be applied to characterize tumor fracture under more realistic interstitial flow conditions.
I. INTRODUCTION
Metastasis is a complex process involving a massive spread of cancer cells from a primary malignant tumor to multiple sites in the human body.1 Tumor growth, enabled by anomalous tumor cell proliferation, relies on tumor angiogenesis,2 the generation of an intratumoral vascular system that provides tumor cells with nutrients. Tumor angiogenesis typically results in a disorganized and leaky vasculature, which enhances leakage from arterial blood capillaries to the tumor environment due to the difference in hydrostatic and osmotic pressures. Part of the fluid returns to the venules, which results in interstitial flow from the arterioles and capillaries to the venules.3 This flow is insufficient to restore normal pressure values, leading to elevated interstitial fluid pressures at the tumor core.4 Moreover, the development of new lymphatic vessels in the tumor, known as lymphangiogenesis,5 is minor and does not match the massive blood vessel development provided by angiogenesis.6 This results in significant high interstitial flow out of the tumor to eventually drain into the lymphatic system surrounding it [see Fig. 1(a)]. This directional interstitial flow becomes the essential transporter of both nutrients and signaling molecules to cancer cells and their surrounding environment.3,7
Because of its very low velocity (from 0.1 to ),8,9 the dominant mechanisms by which interstitial flow acts on tumor cells are assumed to be advection and diffusion, rather than flow shear.3,7,10 However, whereas interstitial flow velocity is low, its driving pressure is high. Measures conducted in human patients’ tumors11–15 demonstrated the existence of pressures of up to (or ).14,16 Our previous work17 showed that an intratumoral pressure difference higher than applied on a millimetric 3D cellular aggregate, an in vitro tumor model, caused aggregate deformation, permeabilization, and fracture. Such fracture triggers a massive detachment of cells from the tumor, which may lead to metastasis initiation. Recently, Huang et al.18 also observed that tumor spheroids seeded within the collagen gel scaffold inside a microfluidic device “exploded” under interstitial flow, which provides evidence that fracture can occur even within the extracellular matrix. Thus, understanding and characterizing tumor fracture under flow will shed light on a potentially important and largely unexplored mechanism of the metastasis initiation.
In this article, we present a detailed characterization of fracture in a 3D model tumor, based on multiple microfluidic assays under various interstitial flow conditions. Our study was conducted using cellular aggregates, which are a well-established in vitro model to study fundamental physical mechanisms that could be extrapolated to real tumors.19–22 Aggregates were placed inside a specifically designed microfluidic device that allows applying a controlled flow while simultaneously measuring the time-evolution of the applied pressure and imaging aggregate deformation.
II. METHODOLOGY
A. Microfluidic design
Our microfluidic design aims to mimic the increased interstitial fluid pressure at the tumor core and the outward force that it exerts onto a section of a tumor [Fig. 1(a)]. Here, the increased pressure is mimicked by imposing a value of the flow rate at the flow inlet. Flow traverses a chamber designed to house a biological sample, which may contain a cellular aggregate or a collagen gel scaffold, and exits through the flow outlet. An auxiliary channel, labeled “sample input,” is needed to introduce the biological sample into the chamber. Two additional channels upstream and downstream of the chamber are connected to two manometers to measure the flow-induced pressure drop. We developed two design variations for the chamber applicable to two types of in vitro tumor assays: (1) hydrogel assays, where cells are suspended in a hydrogel solution that is injected into the chamber and then gelified to create a scaffold for the cells;23–29 (2) cellular aggregate assays, where cellular aggregate spheroids behaving like living viscoelastic droplets30,31 are fabricated and then pushed into the chamber.17 For hydrogel assays, we have a design consisting of 5 microchannels radially linked to a rectangular cuboid chamber [Fig. S1(a) in the supplementary material]. This design is appropriate for high permeability samples such as hydrogels but not optimal for low permeability samples such as multicellular spheroids (see the supplementary material for details on the design of hydrogels). Moreover, the pressure developed in the closed input channel upstream, due to flow infusion by the syringe pump, cannot be easily relieved. The setup thus yields rapidly increasing upstream pressures that are difficult to control and that often generate experimental artifacts. The setup thus proved inadequate for our cell aggregate experiments, where we needed to precisely control the rate of pressure difference increase and where we wished to investigate both low and high rates of pressure difference variation. For cellular aggregate assays, we develop another design featuring a narrow side channel in parallel with the sample chamber [Fig. 1(b)]. The input and output channels remain connected through this side channel, which helps to regulate the pressure rise induced by very low permeability samples, such as our cellular aggregates before fracture occurs. Because the hydrodynamic resistance of the side channel is known, this design allows modulating the pressure difference applied to the aggregate in the chamber by varying the total input flow rate driven by a programmable syringe pump (KDS Legato 210P, KD Scientific, MA, USA) with a response time of seconds. At the two ends of the side channel, we connect two digital manometers (HD 755-0.5 psi, Extech Instrument, MA, USA) to record the evolution of over time. The hydrodynamics of our setup can be illustrated by an analogy with a simple electric circuit of two resistors in parallel [Fig. 1(c)]. For our design’s dimensions, we performed a calibration assay to measure the side channel hydrodynamic resistance of (standard deviation, ) for a flow of Dulbecco's Modified Eagle Medium (DMEM) culture medium at (Fig. S2(a) in the supplementary material) going through the side channel while the sample chamber is completely blocked. Device dimensions are summarized in Fig. 1(b). In another test, we assessed the ability of our system to generate a step-by-step variation of (Fig. S2(b) in the supplementary material), which is applicable to in vitro assays that require a complex time-dependent pressure input.
B. Device fabrication
We fabricate our microfluidic devices with a vertical thickness of in Polydimethylsiloxane (PDMS) (Sylgard 184, Dow Chemical, Midland, MI, USA) by a standard soft-lithography technique.17,32–35 First, the master mold is fabricated by photolithography with SU-8 2100 to achieve thickness. Then, we mold the master in the PDMS solution with the curing agent at a ratio of 10:1. The PDMS chips are cured for 4 h in an oven at , and then bonded to glass slides by a plasma cleaner (Harrick Plasma PDC-001, Ithaca, NY). Right after the plasma bonding, the devices are coated with the fibronectin solution (F1411, Sigma-Aldrich, St. Louis, MO) at a concentration of and incubated at for at least 4 h. This coating enables a strong adhesion between cells and channel walls.
C. Cellular aggregate production and experimental preparation
We produce cellular aggregates using the orbital shaking technique17,36,37 from MCF-7 breast cancer cells (HTB-22, ATCC, Manassas, VA). Cells are cultured in 89% DMEM (cat. 10569-010, ThermoFisher), supplemented with 10% fetal bovine serum (cat. 10270-106, ThermoFisher), and penicillin-streptomycin (cat. 15140-148, ThermoFisher), and they are kept in an incubator (Heracell VIOS 160i, ThermoFisher) at and . When the cultured cells become confluent, we trypsinize and suspend them in of fresh -equilibrated culture medium. A suspension to a final concentration of is prepared in a small Erlenmeyer flask. We place the flask inside an incubated shaker (LM-420D, Yihder Technology, Xinbei City, Taiwan) spinning at and for 20 h. With this setting, we produce spheroidal cellular aggregates ranging from 50 to in diameter.
For each experiment, we select one cellular aggregate spheroid with a size between 200 and , similar to our previous study17 (note that multicellular spheroids used in Ref. 17 were also larger than , and not larger than , as mistakenly stated in this earlier publication). We avoid larger aggregates because they contain dead cells at their core due to the lack of nutrients. The spheroid is introduced into the sample inlet by a micropipette, then pushed to the sample chamber by the periodical compression method.17 Behaving as a viscoelastic drop, the cellular aggregate deforms and squeezes through the sample input channel, to adopt a flattened shape and fill the sample chamber. The cellular aggregate is then kept in -equilibrated culture medium at under no flow. This resting stage lasts for 2 h to let the cellular aggregate firmly adhere to the channel walls38 and attain an equilibrium shape. The cell-wall adhesion is very important in this study. In the previous study,17 we have reported that failure in cell-wall adhesion would result in the cellular aggregate being washed off the sample chamber very fast (see the supplementary material of Ref. 17). Thus, fracture would not be achieved.
III. RESULTS AND DISCUSSION
A. Cellular aggregate’s behavior under increasing interstitial pressure
Each experimental run started with . was increased from 0 at a constant flow loading rate, . Figure 2(a) shows an example of a cellular aggregate first deforming and then fracturing under [see the supplementary material (Movie 1) for the full experimental run]. We jointly plot the recorded pressure difference and the aggregate length in Fig. 2(b) to analyze how the aggregate deforms over time. was retrieved from images of the aggregate shape over time using Fiji.17,39 We repeated the experiment with different values of and observed a viscoelastic behavior of cellular aggregates, consistent with previous findings.17,20,37 The behavior of a cellular aggregate under increasing interstitial pressure can be described as a 3-stage sequence: “deform,” “fracture,” and “explode” [Fig. 2(c)].
Deform. Starting from the resting state at , the increase of induced aggregate deformation. During this stage, we observed cracks progressing inside the aggregate. We retrieved images of the crack pathways by image processing with Fiji [Fig. 2(c0-1)]. The processed images had been obtained from raw images by applying a bandpass filter which only retains features larger than the size of a single cell. Then, the crack pathways were drawn and analyzed using MTrackJ40 [see the supplementary material (Movie 2) for an example of processed images of fracture pathways developed in a cellular aggregate under ]. The details of the image analysis procedure are presented in the supplementary material.
Fracture. Upon reaching a critical pressure (), aggregate fracture occurred. Fracture corresponds to one or multiple visible cracks spanning the aggregate length [Fig. 2(c2)], and it was also signaled by a sudden drop of [Fig. 2(b2)]. The time when fracture occurred is defined as , which is a relevant quantifier of aggregate fracture.
Explode. Fracture led to severe damage to the cellular aggregate structure. A marked drop of signals the fracture event. The resulting increase in interstitial flow through fracture pathways rapidly enlarged the cracks, disassembled large regions of the aggregate, and eventually washed away big portions of it. We call this aggregate disassembling process “aggregate explosion” [Fig. 2(c3)].
B. Viscoelastic model of cellular aggregate under time-dependent pressure
Previous studies17,20,31 described the viscoelastic behavior of a cellular aggregate by Zener’s model consisting of an elastic spring in parallel with a series of another spring and a damper [Fig. 3(a)]. The pressure difference applied to the aggregate causes it to deform with a strain following the relation
(1) |
where is the strain rate, and the parameters , , were experimentally obtained previously.17 If we assume , then . Under this hypothesis, the solution to Eq. (1) is
(2) |
This solution suggests the existence of a characteristic time , which separates two viscoelastic deformation regimes [illustrated in Fig. 2(b)].
(i) At the short-time limit, where , we have the primary creeping with
(3) |
showing a quadratic variation of the aggregate strain over time,
(ii) at the long-time limit, where , we have the secondary creeping with
(4) |
which indicates a linear deformation of the aggregate over time.
We also see that the rate of increase of aggregate strain is proportional to the loading rate and thus sensitive to it.
C. Fracture characterization under different flow loading rates
1. Fracture energy and critical pressure
From the physics of adhesion, we know that fracture occurs when a certain amount work has been applied to the system and thus corresponds to a critical energy. It is however more common to report a critical force (or a critical pressure) in experiments, because in many systems, there is an equivalence between the critical energy and the critical force, as we discuss here for the case of aggregate fracture. The work exerted on the aggregate by the interstitial pressure over the time required to fracture, , is . By substituting Eq. (1) into , we obtain
(5) |
where is the initial length of the cellular aggregate and is the aggregate strain at fracture. We can estimate the latter by using Eq. (4) to write , where is the critical pressure difference that induces aggregate fracture. Thus, the critical pressure depends on as follows:
(6) |
We previously showed17 that fracture energy depends on the loading rate in a way similar to that described for polymers.41 Introducing this expression for into Eq. (6), we theoretically predict compared to our experimental data in Fig. 3(b). The dependence of on has an identical shape to that of the fracture energy , which was discussed in our previous work.17 Thus, aggregate fracture can be described either in terms of a critical energy, which has a direct physical interpretation, or in terms of a critical pressure, which is usually a more straightforward measurement. We emphasize that the whole range of fracture pressures in Fig. 3(b) can be reached in in vivo tumors, where pressures as high as have been recorded,14,16 which supports the physiological relevance of our study.
2. Time to fracture
Here, we investigate the time needed for the aggregate fracture to happen () as a function of the loading rate . Figure 3(c) shows that decreases as increases in experiment. Considering that is built up due to flow limitation by the side channel, i.e., if we assume , we can write . Combining this with Eq. (6), we obtain the following relationship between and :
(7) |
With the expression of from the previous study,17 we plot our predicted as a function of in Fig. 3(c), showing very good agreement with the experimental data. We note that when , , which implies that for such high loading rates, cellular aggregates only undergo primary creeping as described by Eq. (3). This theoretical model of indicates that a very low flow loading rate results in aggregate fracture at the lowest critical pressure ; however, it requires a duration of to fracture. This could illustrate a possibility for a tumor to fracture and initiate metastasis even under a slowly increasing intratumoral pressure. In the cases of high loading rates, the pressure builds up very fast and fracture might happen over durations of minutes.
3. Aggregate strain at fracture
Next, we quantify maximum aggregate deformation right before fracture. With given by Eq. (7), we predict aggregate strain at fracture, , by Eq. (2). As shown in Fig. 3(d), this prediction qualitatively agrees with the experimental data, which shows that the aggregate deformed less as increases. Specifically, the experimental difference of between low loading rates ranging from 0.2 to is insignificant (p-value, ). However, the strain significantly decreases at high loading rates, from 0.2 to () and from 0.8 to (). The fast increasing pressure made the aggregate fracture in a short period of time where the maximum aggregate deformation was limited by its viscosity. We note that, at and , the experimental data of are higher than the values of the viscoelastic model. We hypothesize that this discrepancy may arise from aggregate architecture disassembly and rearrangement under high loading rates, which could be interpreted as the aggregate deforming over the elastic limit and behaving as a plastic material.
4. Fracture pathways
We collect images of the fracture pathways under different [see Fig. 4(a)] and quantify pathway curvature by its tortuosity , where is the total curvilinear length of a pathway, and the straight-line distance between its two ends. Due to the directionality of the pressure gradient, the tortuosity values at fracture () indicate rather straight fracture pathways regardless of the loading rate [see Fig. 4(b)]. We present the tortuosity data in the supplementary material (Table S1). The tortuosity at appears to be slightly larger on average than that at higher , even if this experimental result is not significant due to the large standard deviations. This suggested that the increase of tortuosity with decreasing can be explained from the larger deformation of the aggregate at lower loading rates. Due to high aggregate stretching along the flow direction, cell-cell adhesions are weakened, particularly across the flow direction. This would result in more randomly oriented fracture pathways, consistent with both a higher value of the average tortuosity and of its standard deviation.
We next investigate the pathway velocity , which we define as the average one-dimensional growth, measured along the main channel, of all the fracture pathways, i.e., , where is the total growth along the channel direction of pathways over a time . In Figs. 4(c) and 4(d), we report two values of for each . These are the average pathway velocities during the “deform” stage and during the “explode” stage. Aggregate fracture occurs at the transition between “deform” and “explode” stages. During the “deform” stage, the pathways have not yet reached the full length of the aggregate. In the “explode” stage, all the pathways reach the full aggregate length over a short time, yielding significantly higher values of the pathway velocity. Our data show that the average velocity of the fracture pathways does not significantly depend on [Fig. 4(c)] during the “deform” stage. The “explode” velocity, however, significantly increases with increasing [Fig. 4(d)].
The development of fracture pathways has been studied here in the absence of extra-cellular matrix (ECM). We expect that the eventual presence of ECM will have an effect on fracture pathway development. On the one hand, ECM may provide mechanical resistance against fracture. On the other hand, ECM shielding yields higher interstitial pressure.10 These opposing effects are relevant to advanced tumors. For instance, cancerous epithelial cells can signal local fibroblasts to form myofibroblasts, which can secrete significant amounts of ECM proteins.10,42 This stroma-epithelial association is called “desmoplastic reaction” which stiffens the tissues surrounding the tumor43 but also contributes to the high pressures recorded in vivo, which can be up to one order of magnitude higher than those obtained in our experiments.14,16 How these effects of ECM modify the fracture phenomenon in advanced tumors is an open question, which can be addressed by future in vitro studies using ECM scaffolds.
5. Permeability of aggregate fracture
During the “deform” stage, the cellular aggregate progressively becomes more permeable due to its deformation. The flow rate going through the aggregate is determined as [see the inset of Fig. 1(b)], and the intrinsic permeability of the cellular aggregate is estimated as , with being the length of the cellular aggregate, being the cross-sectional area, and being the viscosity of the culture medium. Figure 4(e) shows the aggregate’s intrinsic permeability in reference with the constant permeability of the side channel right at the time when fracture is reached, as a function of the applied . The constant permeability of the side channel () is taken as a reference. Note that, after fracture, a big fragment of the aggregate is removed, which makes the calculation no longer valid. We observe that at fracture, which we note is highest for . Then, decreases as increases up to . Beyond , varies insignificantly around an estimated minimal value of , which is comparable to the average intrinsic permeability of the collagen gel.17,27 Converting to hydraulic resistance ratio, we obtain at , and for to . Thus, fracture damages cellular aggregates so that their hydrodynamic resistance can become as low as that of the side channel. This is to be compared with the initial aggregate state, when aggregate resistance is much higher than that of the side channel (initial ). Aggregate fracture damage beyond may be precluded in our device by the presence of the side channel. In another words, the side channel limits any further damage to the cellular aggregate due to the parallel configuration between the sample chamber and the side channel. As increases to 1, the total resistance of the whole system is accordingly reduced by half, causing a drastic decrease of and a balance of flow rates through the side channel and the sample chamber.
IV. CONCLUSION
This study investigates the quantitative characteristics of fracture occurring in a model tumor subjected to increasing interstitial fluid pressure. We study the viscoelastic deformation of the aggregates under interstitial flow and described two regimes: a short-time viscoelastic regime and a long-time elastic regime, followed by fracture once the interstitial pressure becomes high enough. We demonstrate that aggregate fracture can either be quantified by a critical energy or equivalently by a critical pressure. In our system, the flow loading rate of results in aggregate fracture at the highest critical pressure of 1200 Pa. Loading rates higher than cause fracture at a slightly lower critical pressure. The critical pressure is lowest () at very slow loading rates. Our theoretical conceptualization of the aggregate behavior under interstitial pressure successfully explains the observed variations of the time to fracture and of the maximum strain as a function of the loading rate, . The time to fracture increases when decreases. Our model predicts that a tumor may fracture under a slow but sustained development of intratumoral pressure, which in our experimental system requires a duration longer than an hour. In contrast, high loading rates can result in tumor fracture within minutes. In a real tumor, intratumoral pressure fluctuates over time. Thus, investigations accounting for pressure fluctuations and for the complex tumor environment would be needed in order to extrapolate our results. Aggregate permeability is significantly enhanced by fracture, in a way that depends on the loading rate. Lower enhances aggregate deformation and fracture damage. Higher induces a more fragile aggregate behavior. In the latter case, fracture occurs rapidly but fracture damage, as quantified by the resulting permeability, remains more limited. Through the theoretical model, we also learn that changing the size of the input channel or the sample chamber containing the cellular aggregate will affect the fracture energy and critical pressure of the aggregate. However, we expect the viscoelastic parameters such as , , to only depend on the material of the tumor or the cell-cell adhesion. Thus, our model should be applicable to different aggregate sizes and cell types.
Overall, our studies of fracture in a model tumor indicate that fracture characteristics are very sensitive to temporal variations in interstitial pressure. This is an important result, because intratumoral pressure continuously varies in in vivo conditions, both temporally and spatially, due to blood pressure variations and to the heterogeneity of the complex tumor microenvironment. Moreover, the presence of extra-cellular matrix in advanced tumors is expected to increase mechanical strength but also interstitial pressure, due to the stiffened stroma. It is thus emphasized that our measured parameter values correspond to our in vitro model, and care should be taken when extrapolating these values to in vivo conditions. To narrow the gap between in vitro and in vivo, future studies need to extend the approach presented here to investigate more realistic conditions of interstitial pressure and extra-cellular matrix support, such as by considering periodically varying pressure inputs and by using tumor cells embedded in an ECM scaffold.
SUPPLEMENTARY MATERIAL
ACKNOWLEDGMENTS
We acknowledge the financial support from NTU SUG grant (No. M4080741.050).
Contributor Information
Marcos, Email: .
David Gonzalez-Rodriguez, Email: .
REFERENCES
- 1.Poste G. and Fidler I. J., Nature 283, 139 (1980). 10.1038/283139a0 [DOI] [PubMed] [Google Scholar]
- 2.Folkman J., Semin. Oncol. 29, 15 (2002). 10.1053/sonc.2002.37263 [DOI] [PubMed] [Google Scholar]
- 3.Swartz M. A. and Lund A. W., Nat. Rev. Cancer 12, 210 (2012). 10.1038/nrc3186 [DOI] [PubMed] [Google Scholar]
- 4.Butler T. P., Grantham F. H., and Gullino P. M., Cancer Res. 35, 3084 (1975). [PubMed] [Google Scholar]
- 5.Dadiani M., Kalchenko V., Yosepovich A., Margalit R., Hassid Y., Degani H., and Seger D., Cancer Res. 66, 8037 (2006). 10.1158/0008-5472.CAN-06-0728 [DOI] [PubMed] [Google Scholar]
- 6.Sleeman J., Schmid A., and Thiele W., Semin. Cancer Biol. 19, 285 (2009). 10.1016/j.semcancer.2009.05.005 [DOI] [PubMed] [Google Scholar]
- 7.Swartz M. A. and Fleury E., Annu. Rev. Biomed. Eng. 9, 229 (2007). 10.1146/annurev.bioeng.9.060906.151850 [DOI] [PubMed] [Google Scholar]
- 8.Dafni H., Israely T., Bhujwalla Z. M., Benjamin L. E., and Neeman M., Cancer Res. 62, 6731 (2002). [PubMed] [Google Scholar]
- 9.Chary S. R. and Jain R. K., Proc. Natl. Acad. Sci. U.S.A. 86, 5385 (1989). 10.1073/pnas.86.14.5385 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Shieh A. C. and Swartz M. A., Phys. Biol. 8, 015012 (2011). 10.1088/1478-3975/8/1/015012 [DOI] [PubMed] [Google Scholar]
- 11.Boucher Y., Kirkwood J. M., Opacic D., Desantis M., and Jain R. K., Cancer Res. 51, 6691 (1991). [PubMed] [Google Scholar]
- 12.Less J. R., Posner M. C., Boucher Y., Borochovitz D., Wolmark N., and Jain R. K., Cancer Res. 52, 6371 (1992). [PubMed] [Google Scholar]
- 13.Gutmann R., Leunig M., Feyh J., Goetz A. E., Messmer K., Kastenbauer E., and Jain R. K., Cancer Res. 52, 1993 (1992). [PubMed] [Google Scholar]
- 14.Curti B. D., Urba W. J., Alvord W. G., Janik J. E., Smith J. W., Madara K., and Longo D. L., Cancer Res. 53, 2204 (1993). [PubMed] [Google Scholar]
- 15.Nathanson S. D. and Nelson L., Ann. Surg. Oncol. 1, 333 (1994). 10.1007/BF03187139 [DOI] [PubMed] [Google Scholar]
- 16.Heldin C.-H., Rubin K., Pietras K., and Östman A., Nat. Rev. Cancer 4, 806 (2004). 10.1038/nrc1456 [DOI] [PubMed] [Google Scholar]
- 17.Tran Q. D., Marcos, and Gonzalez-Rodriguez D., Soft Matter 14, 6386 (2018). 10.1039/C8SM00844B [DOI] [PubMed] [Google Scholar]
- 18.Huang Y. L., Ma Y., Wu C., Shiau C., Segall J., and Wu M., in APS March Meeting Abstracts (American Physical Society, 2019), p. K66.002.
- 19.Mueller-Klieser W., J. Cancer Res. Clin. Oncol. 113, 101 (1987). 10.1007/BF00391431 [DOI] [PubMed] [Google Scholar]
- 20.Gonzalez-Rodriguez D., Bonnemay L., Elgeti J., Dufour S., Cuvelier D., and Brochard-Wyart F., Soft Matter 9, 2282 (2013). 10.1039/c2sm26648b [DOI] [Google Scholar]
- 21.Lin R.-Z. and Chang H.-Y., J. Biotechnol. 3, 1172 (2008). 10.1002/biot.200700228 [DOI] [PubMed] [Google Scholar]
- 22.Beaune G., Blanch-Mercader C., Douezan S., Dumond J., Gonzalez-Rodriguez D., Cuvelier D., Ondarçuhu T., Sens P., Dufour S., Murrell M. P. et al., Proc. Natl. Acad. Sci. U.S.A. 115, 12926 (2018). 10.1073/pnas.1811348115 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Vickerman V., Blundo J., Chung S., and Kamm R. D., Lab Chip 8, 1468 (2008). 10.1039/b802395f [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Chung S., Sudo R., Mack P. J., Wan C.-R., Vickerman V., and Kamm R. D., Lab Chip 9, 269 (2009). 10.1039/B807585A [DOI] [PubMed] [Google Scholar]
- 25.Shin Y., Han S., Jeon J. S., Yamamoto K., Zervantonakis I. K., Sudo R., Kamm R. D., and Chung S., Nat. Protoc. 7, 1247 (2012). 10.1038/nprot.2012.051 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Zervantonakis I. K., Hughes-Alford S. K., Charest J. L., Condeelis J. S., Gertler F. B., and Kamm R. D., Proc. Natl. Acad. Sci. U.S.A. 109, 13515 (2012). 10.1073/pnas.1210182109 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Polacheck W. J., Zervantonakis I. K., and Kamm R. D., Cell. Mol. Life Sci. 70, 1335 (2013). 10.1007/s00018-012-1115-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Haessler U., Teo J. C., Foretay D., Renaud P., and Swartz M. A., Integr. Biol. 4, 401 (2012). 10.1039/c1ib00128k [DOI] [PubMed] [Google Scholar]
- 29.Huang Y. L., Tung C.-K., Zheng A., Kim B. J., and Wu M., Integr. Biol. 7, 1402 (2015). 10.1039/C5IB00115C [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Phillips H. and Steinberg M., J. Cell Sci. 30, 1 (1978). [DOI] [PubMed] [Google Scholar]
- 31.Guevorkian K., Gonzalez-Rodriguez D., Carlier C., Dufour S., and Brochard-Wyart F., Proc. Natl. Acad. Sci. U.S.A. 108, 13387 (2011). 10.1073/pnas.1105741108 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Whitesides G. M., Ostuni E., Takayama S., Jiang X., and Ingber D. E., Annu. Rev. Biomed. Eng. 3, 335 (2001). 10.1146/annurev.bioeng.3.1.335 [DOI] [PubMed] [Google Scholar]
- 33.Marcos and Stocker R., Limnol. Oceanogr. Methods 4, 392 (2006). 10.4319/lom.2006.4.392 [DOI] [Google Scholar]
- 34.Marcos, Fu H. C., Powers T. R., and Stocker R., Phys. Rev. Lett. 102, 158103 (2009). 10.1103/PhysRevLett.102.158103 [DOI] [PubMed] [Google Scholar]
- 35.Tran Q. D., Kong T. F., Hu D., Marcos, and Lam R. H., Lab Chip 16, 2813 (2016). 10.1039/C6LC00615A [DOI] [PubMed] [Google Scholar]
- 36.Ryan P. L., Foty R. A., Kohn J., and Steinberg M. S., Proc. Natl. Acad. Sci. U.S.A. 98, 4323 (2001). 10.1073/pnas.071615398 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Guevorkian K., Colbert M.-J., Durth M., Dufour S., and Brochard-Wyart F., Phys. Rev. Lett. 104, 218101 (2010). 10.1103/PhysRevLett.104.218101 [DOI] [PubMed] [Google Scholar]
- 38.Douezan S., Guevorkian K., Naouar R., Dufour S., Cuvelier D., and Brochard-Wyart F., Proc. Natl. Acad. Sci. U.S.A. 108, 7315 (2011). 10.1073/pnas.1018057108 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B. et al., Nat. Methods 9, 676 (2012). 10.1038/nmeth.2019 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Meijering E., Dzyubachyk O., and Smal I., in Methods in Eenzymology (Elsevier, 2012), Vol. 504, pp. 183–200. [DOI] [PubMed]
- 41.Saulnier F., Ondarçuhu T., Aradian A., and Raphaël E., Macromolecules 37, 1067 (2004). 10.1021/ma021759t [DOI] [Google Scholar]
- 42.Insana M. F., Pellot-Barakat C., Sridhar M., and Lindfors K. K., J. Mammary Gland Biol. Neoplasia 9, 393 (2004). 10.1007/s10911-004-1409-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Krouskop T. A., Wheeler T. M., Kallel F., Garra B. S., and Hall T., Ultrason. Imaging 20, 260 (1998). 10.1177/016173469802000403 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.